Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | METAP2 | P50579 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 4/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402725 | 0.91 | BCHE (0.46) | BCHEALDH1A1ELANEF2KLK7 | |
| SCHEMBL14478921 | 0.84 | BCHE (0.49) | BCHEALDH1A1METAP2KLK7KLK5 | |
| SCHEMBL404401 | 0.84 | BCHE (0.49) | BCHEALDH1A1METAP2KLK7KLK5 | |
| SCHEMBL14362993 | 0.84 | BCHE (0.49) | BCHEALDH1A1METAP2KLK7KLK5 | |
| SCHEMBL402527 | 0.77 | BCHE (0.45) | BCHEALDH1A1METAP2ELANEF2 | |
| SCHEMBL403509 | 0.77 | BCHE (0.45) | BCHEALDH1A1METAP2ELANEF2 | |
| SCHEMBL404367 | 0.76 | BCHE (0.44) | BCHEALDH1A1KLK7KLK5TSHR | |
| SCHEMBL19749101 | 0.75 | ALDH1A1 (0.52) | ALDH1A1TSHR | |
| SCHEMBL29433900 | 0.75 | ALDH1A1 (0.52) | ALDH1A1TSHR | |
| SCHEMBL16648788 | 0.75 | ALDH1A1 (0.52) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | BCHE 1419/4885ALDH1A1 371/4885METAP2 1897/4885 |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | BCHE 1409/4885ALDH1A1 364/4885METAP2 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.